240 related articles for article (PubMed ID: 17190647)
1. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Tonra JR; Hicklin DJ
Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
[TBL] [Abstract][Full Text] [Related]
2. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
3. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
4. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
6. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
8. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
12. The present and future of angiogenesis-directed treatments of colorectal cancer.
O'Dwyer PJ
Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Carrato A; Gallego-Plazas J; Guillen-Ponce C
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1385-96. PubMed ID: 17069524
[TBL] [Abstract][Full Text] [Related]
14. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
15. Delta-like 4/Notch signaling and its therapeutic implications.
Yan M; Plowman GD
Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitors in the management of breast cancer.
Bossung V; Harbeck N
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):79-86. PubMed ID: 19952746
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
19. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
20. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
